Advertisement

Pharmacy World and Science

, Volume 28, Issue 4, pp 194–198 | Cite as

Impact of the reclassification of omeprazole on the prescribing and sales of ulcer healing drugs

  • Teerapon DhippayomEmail author
  • Roger Walker
Original paper

Abstract

Objectives

To investigate if the reclassification of omeprazole from a prescription only medicine to pharmacy sale status had an impact on the prescribing and sales of ulcer-healing drugs and whether deprivation had any influence on this.

Setting

Primary care, Wales, UK.

Method

Retrospective analysis (March 2002 to February 2005) of prescription data and pharmacy sales data.

Main outcome measure

Number of items per 1,000 population.

Results

The number of prescription items for ulcer-healing drugs across Wales increased in each year of the study. The number of items per 1,000 population for proton pump inhibitors increased by 12.4% (473.3 to 531.8 items) in 2003/04 and 13.8% (531.8 to 605.1 items) in 2004/05, whereas the number of items per 1,000 population for H2 antagonists fell by 6.2% (149.1 to 139.9 items), and 5.7% (139.9 to 131.9 items) during 2003/04 and 2004/05, respectively. The sale of items per 1,000 population of H2 antagonists increased by 34.3% (19.8 to 26.6 items) in 2003/04, but fell by 8.6% (26.6 to 24.3 items) in 2004/05. In February 2005, 12 months after reclassification, omeprazole accounted for 7.6% (2.0 items per 1,000 population) of the total sales (26.3 items per 1,000 population) of ulcer-healing drugs from pharmacies in Wales. Areas with high multiple deprivation and unemployment were significantly associated with the prescribing of ulcer-healing drugs, H2 antagonists and proton pump inhibitors. Multiple deprivation, unemployment and low income explained 21% of the variation in prescribing of ulcer-healing drugs. The sale of omeprazole through pharmacies was not related to these deprivation characteristics.

Conclusion

Twelve months after the reclassification of omeprazole the market growth of H2 antagonists sold from pharmacies was halted although there was no apparent impact on␣the prescription of ulcer-healing drugs. As a consequence there was no saving to the health service drug␣budget associated with the reclassification of omeprazole.

Keywords

Omeprazole OTC Over the counter Prescribing Reclassification Ulcer-healing drugs 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgement

This study was supported by funding from the Welsh Assembly Government.

Conflict of interests None declared.

References

  1. 1.
    Medicines, ethics & practice: a guide for pharmacists. The Royal Pharmaceutical Society of Great Britain, London, 2003.Google Scholar
  2. 2.
    Blenkinsopp J. Out of the dispensary and into the pharmacy—POM-to-P switching. Pharm J 2004;272:508–9.Google Scholar
  3. 3.
    Cohen JP, Paquette C, Cairns CP. Switching prescription drugs to over the counter. BMJ 2005;330:39–41.PubMedCrossRefGoogle Scholar
  4. 4.
    Ryan M, Yule B (1990) Switching drugs from prescription-only to over-the-counter availability: economic benefits in the United Kingdom. Health Policy 16:233–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Bond C. POM to P—implications for practice pharmacists. Prim Care Pharm 2002;2:5–7.Google Scholar
  6. 6.
    Omeprazole goes over-the-counter as Zanprol. Pharm J 2004;272: 305.Google Scholar
  7. 7.
    Ryan M, Birch S. Charging for health care: evidence on the utilisation of NHS prescribed drugs. Soc Sci Med 1991;33:681–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Jones I, Britten N. Why do some patients not cash their prescriptions? Br J Gen Pract 1998;48:903–5.PubMedGoogle Scholar
  9. 9.
    Senior ML, Williams H, Higgs G. Morbidity, deprivation and drug prescribing: factors affecting variations in prescribing between doctors’ practices. Health Place 2003;9:281–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Williams D, Teljeur C, Bennett K, Kelly A, Feely J. Influence of material deprivation on prescribing patterns within a deprived population. Eur J Clin Pharmacol 2003;59:559–63.PubMedCrossRefGoogle Scholar
  11. 11.
    Christensen R. Analysis of variance, design and regression: applied statistical methods. Chapman & Hall, London, 1998.Google Scholar
  12. 12.
    Bellingham C. Overhaul of POM-to-P reclassification could mean big changes for pharmacy. Pharm J 2002;268:131–3.Google Scholar
  13. 13.
    Royal Pharmaceutical Society of Great Britain. Practice guidance: OTC omeprazole, May 2004. http:/www.rpsgb.org/pdfs.otcomeprazoleguide.pdf (25 Dec 2005)Google Scholar
  14. 14.
    Andrade SE, Gurwitz JH, Fish LS. The effect of an Rx- to-OTC switch on medicaiton prescribing patterns and utilization of physician services: the case of H2-receptor antagonists. Med Care 1999;37:424–30.PubMedCrossRefGoogle Scholar
  15. 15.
    Bellingham C. To switch or not: pharmacists opinions. Pharm J 2002;268:607.Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  1. 1.Welsh School of PharmacyCardiff UniversityCardiffUK
  2. 2.National Public Health Service for Wales, Temple of Peace & HealthCardiffUK

Personalised recommendations